NTLA - Intellia Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

2.649B

Cash

933.5M

Avg Qtr Burn

-90.7M

Short % of Float

7.63%

Insider Ownership

5.61%

Institutional Own.

87.91%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
NTLA-2002 (KLKB1 Inhibitor) Details Hereditary angioedema , Rare diseases, Rare genetic disease	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NTLA-2001 (CRISPR/Cas9) Details Transthyretin amyloidosis	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NTLA-5001 Details Acute myeloid leukemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OTQ923 / HIX763 (Hematopoietic Stem Cells (HSC)) Details Sickle cell disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.